<div id="displayContant">
<br><div class="long-title">
<span>DAKLINZA</span><span> (
					daclatasvir
				)</span>
</div>
<br><div class="section"><div id="DAKLINZA_collapsableElement_48780-1" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"></div></div></div>
<div class="section">
<div id="nonCollapsableElement_34067-9">
<div class="drugSubheadings">
<span id="DAKLINZA_34067-9" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>1 INDICATIONS AND USAGE</div>
<div id="DAKLINZA_previewText_34067-9" class="previewText">
                  DAKLINZA is indicated for use with sofosbuvir for the treatme
                        DAKLINZA is a hepatitis C virus (HCV) NS5A inhibitor in<span>...</span>
</div>
</div>
<div id="DAKLINZA_collapsableElement_34067-9" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText">
<text>
                  <p>DAKLINZA is indicated for use with sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection [<content stylecode="italics">see <a href="#ID_f811910c-7da4-42e0-b693-0db6ceeb64ca">Dosage and Administration (2)</a> and <a href="#ID_369a32e6-767c-41a5-826b-0a0ea2e9b7c7">Clinical Studies (14)</a>
                     </content>].</p>
                  <p>Limitations of Use:</p>
                  <ul ultype="unordered">
                     <li>
                        •Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving DAKLINZA in combination with sofosbuvir for 12 weeks [<content stylecode="italics">see <a href="#ID_369a32e6-767c-41a5-826b-0a0ea2e9b7c7">Clinical Studies (14)</a>
                        </content>].</li>
                  </ul>
               </text><text>
                        <p>DAKLINZA is a hepatitis C virus (HCV) NS5A inhibitor indicated for use with sofosbuvir for the treatment of chronic HCV genotype 3 infection. <a href="#ID_f60e0659-e3d8-44a5-9372-047869643ec2">(1)</a>
                        </p>
                        <p>Limitations of Use:</p>
                        <ul ultype="unordered">
                           <li>
                              •Sustained virologic response (SVR) rates are reduced in patients with cirrhosis. <a href="#ID_369a32e6-767c-41a5-826b-0a0ea2e9b7c7">(14)</a>
                           </li>
                        </ul>
                     </text>
</div></div>
</div>
<div class="section">
<div id="nonCollapsableElement_34068-7">
<div class="drugSubheadings">
<span id="DAKLINZA_34068-7" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>2 DOSAGE AND ADMINISTRATION</div>
<div id="DAKLINZA_previewText_34068-7" class="previewText">
                        
                           
                          <span>...</span>
</div>
</div>
<div id="DAKLINZA_collapsableElement_34068-7" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                        <ul ultype="unordered">
                           <li>
                              •60 mg taken orally once daily with or without food in combination with sofosbuvir. <a href="#ID_3eeb42c6-f748-49f0-9260-3e4d07d9378c">(2.1)</a>
                           </li>
                           <li>
                              •Recommended treatment duration: 12 weeks. <a href="#ID_3eeb42c6-f748-49f0-9260-3e4d07d9378c">(2.1)</a>
                           </li>
                           <li>
                              •Dose modification: Reduce dosage to 30 mg once daily with strong CYP3A inhibitors and increase dosage to 90 mg once daily with moderate CYP3A inducers. <a href="#ID_1afb610a-fb67-4cbc-ae78-8c69ec8773cf">(2.2)</a>
                           </li>
                        </ul>
                     </text></div>
<span id="DAKLINZA_collapsableElement_2_1&nbsp;" class="safetySubheading">2.1&nbsp;Recommended Dosage</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>The recommended dosage of DAKLINZA is 60 mg, taken orally, once daily in combination with sofosbuvir for 12 weeks. DAKLINZA may be taken with or without food.</p>
                        <p>The optimal duration of DAKLINZA and sofosbuvir for patients with cirrhosis has not been established [<content stylecode="italics">see <a href="#ID_369a32e6-767c-41a5-826b-0a0ea2e9b7c7">Clinical Studies (14)</a>
                           </content>].</p>
                        <p>For specific dosage recommendations for sofosbuvir, refer to the respective prescribing information.</p>
                     </text></div>
<span id="DAKLINZA_collapsableElement_2_2&nbsp;" class="safetySubheading">2.2&nbsp;Dosage Modification Due to Drug Interactions</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>Refer to the drug interactions and contraindication sections for other drugs before coadministration with DAKLINZA.</p>
                        <p>
                           <content stylecode="italics">Strong inhibitors of cytochrome P450 enzyme 3A (CYP3A): </content>Reduce the dosage of DAKLINZA to 30 mg once daily when coadministered with strong CYP3A inhibitors using the 30 mg tablet [<content stylecode="italics">see <a href="#ID_93a5ce24-f0c5-41e5-82c9-3d6cb19ade6b">Drug Interactions (7)</a>
                           </content>].</p>
                        <p>
                           <content stylecode="italics">Moderate CYP3A inducers: </content>Increase the dosage of DAKLINZA to 90 mg once daily using an appropriate combination of tablets (three 30 mg tablets or one 60 mg and one 30 mg tablet) when coadministered with moderate CYP3A inducers [<content stylecode="italics">see <a href="#ID_93a5ce24-f0c5-41e5-82c9-3d6cb19ade6b">Drug Interactions (7)</a>
                           </content>]. </p>
                        <p>
                           <content stylecode="italics">Strong CYP3A inducers:</content> DAKLINZA is contraindicated in combination with strong CYP3A inducers [<content stylecode="italics">see <a href="#ID_21aa015e-677d-4e54-b06e-cd268f43b128">Contraindications (4)</a>
                           </content>].</p>
                        <p>Dosage reduction of DAKLINZA for adverse reactions is not recommended.</p>
                     </text></div>
<span id="DAKLINZA_collapsableElement_2_3&nbsp;" class="safetySubheading">2.3&nbsp;Discontinuation of Therapy</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>If sofosbuvir is permanently discontinued in a patient receiving DAKLINZA with sofosbuvir, then DAKLINZA should also be discontinued.</p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_43678-2">
<div class="drugSubheadings">
<span id="DAKLINZA_43678-2" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>3 DOSAGE FORMS AND STRENGTHS</div>
<div id="DAKLINZA_previewText_43678-2" class="previewText">
                  
                     
                        •Tablets: 60 m
                        
                           
                          <span>...</span>
</div>
</div>
<div id="DAKLINZA_collapsableElement_43678-2" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText">
<text>
                  <ul ultype="unordered">
                     <li>
                        •Tablets: 60 mg daclatasvir (equivalent to 66 mg daclatasvir dihydrochloride), light green, biconvex, pentagonal, and debossed with “BMS” on one side and “215” on the other side.</li>
                     <li>
                        •Tablets: 30 mg daclatasvir (equivalent to 33 mg daclatasvir dihydrochloride), green, biconvex, pentagonal, and debossed with “BMS” on one side and “213” on the other side.</li>
                  </ul>
               </text><text>
                        <ul ultype="unordered">
                           <li>
                              •Tablet: 60 mg and 30 mg <a href="#ID_892fd2aa-a494-4dde-8f67-ff5b0a27098f">(3)</a>
                           </li>
                        </ul>
                     </text>
</div></div>
</div>
<div class="section">
<div id="nonCollapsableElement_34070-3">
<div class="drugSubheadings">
<span id="DAKLINZA_34070-3" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>4 CONTRAINDICATIONS</div>
<div id="DAKLINZA_previewText_34070-3" class="previewText">
                  
                     
                        •DAKLINZA is c
                        
                           
                          <span>...</span>
</div>
</div>
<div id="DAKLINZA_collapsableElement_34070-3" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText">
<text>
                  <ul ultype="unordered">
                     <li>
                        •DAKLINZA is contraindicated in combination with drugs that strongly induce CYP3A and, thus, may lead to lower exposure and loss of efficacy of DAKLINZA. Contraindicated drugs include, but are not limited to, those uled in Table 1 [<content stylecode="italics">see <a href="#ID_93a5ce24-f0c5-41e5-82c9-3d6cb19ade6b">Drug Interactions (7)</a> and <a href="#ID_fd973a06-63f8-4471-a2de-584c0a88e03d">Clinical Pharmacology (12.3)</a>
                        </content>].</li>
                  </ul>
                  <table width="100%">
                     <caption>Table 1: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Drugs that are Contraindicated with DAKLINZA</caption>
                     <colgroup><col width="24%">
                     <col width="26%">
                     <col width="50%">
                     </colgroup><thead>
                        <tr>
                           <th align="center" stylecode="Botrule Toprule " valign="top">
                              <content stylecode="bold">Mechanism of Interaction</content>
                           </th>
                           <th align="center" stylecode="Botrule Toprule " valign="top">
                              <content stylecode="bold">Clinical Comment</content>
                           </th>
                           <th align="center" stylecode="Botrule Toprule " valign="top">
                              <content stylecode="bold">Drugs that are Contraindicated with DAKLINZA<sup>a</sup>
                              </content>
                           </th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="3" stylecode="Botrule" valign="top">
                              <sup>a</sup>&nbsp;&nbsp;&nbsp;This table is not a comprehensive ul of all drugs that strongly induce CYP3A.</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td stylecode="Toprule ">
                              <p>Strong induction of CYP3A by coadministered drug</p>
                           </td>
                           <td align="center" stylecode="Toprule ">
                              <p>May lead to loss of virologic response to DAKLINZA</p>
                           </td>
                           <td>
                              <p>
                                 <content stylecode="italics">Anticonvulsants</content>
                                 <br>&nbsp;&nbsp;&nbsp;&nbsp;phenytoin, carbamazepine</p>
                           </td>
                        </tr>
                        <tr>
                           <td></td>
                           <td></td>
                           <td>
                              <p>
                                 <content stylecode="italics">Antimycobacterial agents</content>
                                 <br>&nbsp;&nbsp;&nbsp;&nbsp;rifampin</p>
                           </td>
                        </tr>
                        <tr>
                           <td></td>
                           <td></td>
                           <td>
                              <p>
                                 <content stylecode="italics">Herbal products</content>
                                 <br>&nbsp;&nbsp;&nbsp;&nbsp;St. John’s wort (<content stylecode="italics">Hypericum perforatum</content>)</p>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text><text>
                        <ul ultype="unordered">
                           <li>
                              •Strong inducers of CYP3A, including phenytoin, carbamazepine, rifampin, and St. John’s wort. <a href="#ID_21aa015e-677d-4e54-b06e-cd268f43b128">(4)</a>
                           </li>
                        </ul>
                     </text>
</div></div>
</div>
<div class="section">
<div id="nonCollapsableElement_43685-7">
<div class="drugSubheadings">
<span id="DAKLINZA_43685-7" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>5 WARNINGS AND PRECAUTIONS</div>
<div id="DAKLINZA_previewText_43685-7" class="previewText">
                        
                           
                          <span>...</span>
</div>
</div>
<div id="DAKLINZA_collapsableElement_43685-7" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                        <ul ultype="unordered">
                           <li>
                              •Bradycardia When Coadministered with Sofosbuvir and Amiodarone: Serious symptomatic bradycardia may occur in patients taking amiodarone with sofosbuvir in combination with another HCV direct-acting agent, including DAKLINZA, particularly in patients also receiving beta blockers or those with underlying cardiac comorbidities and/or advanced liver disease. Coadministration of amiodarone with DAKLINZA in combination with sofosbuvir is not recommended. In patients with no alternative treatment options, cardiac monitoring is recommended. (<a href="#ID_373737c1-1c3d-432d-8bc5-64cbc8867b32">5.2</a>, <a href="#ID_4225c82a-ae5b-4b78-82ce-dcbff5089df5">6.2</a>, <a href="#ID_ffe9ad53-99fb-46ee-abce-ac3fdf7343f3">7.3</a>)</li>
                        </ul>
                     </text></div>
<span id="DAKLINZA_collapsableElement_5_1&nbsp;" class="safetySubheading">5.1&nbsp;Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>The concomitant use of DAKLINZA and other drugs may result in known or potentially significant drug interactions, some of which may lead to [<content stylecode="italics">see <a href="#ID_21aa015e-677d-4e54-b06e-cd268f43b128">Contraindications (4)</a> and <a href="#ID_93a5ce24-f0c5-41e5-82c9-3d6cb19ade6b">Drug Interactions (7)</a>
                           </content>]:</p>
                        <ul ultype="unordered">
                           <li>
                              •loss of therapeutic effect of DAKLINZA and possible development of resistance,</li>
                           <li>
                              •dosage adjustments of concomitant medications or DAKLINZA,</li>
                           <li>
                              •possible clinically significant adverse reactions from greater exposures of concomitant drugs or DAKLINZA.</li>
                        </ul>
                        <p>See Table 1 for drugs contraindicated with DAKLINZA due to loss of efficacy and possible development of resistance [<content stylecode="italics">see <a href="#ID_21aa015e-677d-4e54-b06e-cd268f43b128">Contraindications (4)</a>
                           </content>]. See Table 3 for steps to prevent or manage other possible and known significant drug interactions [<content stylecode="italics">see <a href="#ID_93a5ce24-f0c5-41e5-82c9-3d6cb19ade6b">Drug Interactions (7)</a>
                           </content>]. Consider the potential for drug interactions before and during DAKLINZA therapy, review concomitant medications during DAKLINZA therapy, and monitor for the adverse reactions associated with the concomitant drugs.</p>
                     </text></div>
<span id="DAKLINZA_collapsableElement_5_2&nbsp;" class="safetySubheading">5.2&nbsp;Serious Symptomatic Bradycardia When Coadministered with Sofosbuvir and Amiodarone</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>Postmarketing cases of symptomatic bradycardia and cases requiring pacemaker intervention have been reported when amiodarone is coadministered with sofosbuvir in combination with another HCV direct-acting antiviral, including DAKLINZA. A fatal cardiac arrest was reported in a patient receiving a sofosbuvir-containing regimen (ledipasvir/sofosbuvir). Bradycardia has generally occurred within hours to days, but cases have been observed up to 2 weeks after initiating HCV treatment. Patients also taking beta blockers or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. Bradycardia generally resolved after discontinuation of HCV treatment. The mechanism for this bradycardia effect is unknown.</p>
                        <p>Coadministration of amiodarone with DAKLINZA in combination with sofosbuvir is not recommended. For patients taking amiodarone who have no alternative treatment options and who will be coadministered DAKLINZA and sofosbuvir:</p>
                        <ul ultype="unordered">
                           <li>
                              •Counsel patients about the risk of serious symptomatic bradycardia</li>
                           <li>
                              •Cardiac monitoring in an inpatient setting for the first 48 hours of coadministration is recommended, after which outpatient or self-monitoring of the heart rate should occur on a daily basis through at least the first 2 weeks of treatment.</li>
                        </ul>
                        <p>Patients who are taking sofosbuvir in combination with DAKLINZA who need to start amiodarone therapy due to no other alternative treatment options should undergo similar cardiac monitoring as outlined above.</p>
                        <p>Due to amiodarone’s long elimination half-life, patients discontinuing amiodarone just prior to starting sofosbuvir in combination with DAKLINZA should also undergo similar cardiac monitoring as outlined above.</p>
                        <p>Patients who develop signs or symptoms of bradycardia should seek medical evaluation immediately. Symptoms may include near-fainting or fainting, dizziness or lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest pain, confusion, or memory problems [<content stylecode="italics">see <a href="#ID_4225c82a-ae5b-4b78-82ce-dcbff5089df5">Adverse Reactions (6.2)</a> and <a href="#ID_ffe9ad53-99fb-46ee-abce-ac3fdf7343f3">Drug Interactions, Table 3 (7.3)</a>
                           </content>].</p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34084-4">
<div class="drugSubheadings">
<span id="DAKLINZA_34084-4" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>6 ADVERSE REACTIONS</div>
<div id="DAKLINZA_previewText_34084-4" class="previewText">
                  The following serious adverse reactions are described below a
                        Most common adverse reactions (≥10%) observed with DAKL<span>...</span>
</div>
</div>
<div id="DAKLINZA_collapsableElement_34084-4" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText">
<text>
                  <p>The following serious adverse reactions are described below and elsewhere in the labeling:</p>
                  <ul ultype="unordered">
                     <li>
                        •Serious Symptomatic Bradycardia When Coadministered with Sofosbuvir and Amiodarone [<content stylecode="italics">see <a href="#ID_373737c1-1c3d-432d-8bc5-64cbc8867b32">Warnings and Precautions (5.2)</a>
                        </content>].</li>
                  </ul>
               </text><text>
                        <p>Most common adverse reactions (≥10%) observed with DAKLINZA in combination with sofosbuvir were headache and fatigue. <a href="#ID_f7896630-2044-406f-a4b6-77949c654045">(6.1)</a>
                        </p>
                        <p>&nbsp;&nbsp;&nbsp;</p>
                        <p>
                           <content stylecode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content stylecode="bold">Bristol-Myers Squibb at 1-800-721-5072</content>
                           <content stylecode="bold"> or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a>
                           </content>
                        </p>
                     </text>
</div>
<span id="DAKLINZA_collapsableElement_6_1" class="safetySubheading">6.1 Clinical Trials Experience</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
                        <p>Approximately 1900 subjects with chronic HCV infection have been treated with the recommended dose of DAKLINZA in combination with other anti-HCV drugs in clinical trials.</p>
                        <p>In the ALLY-3 trial, 152 treatment-naive and treatment-experienced subjects with HCV genotype 3 infection were treated with DAKLINZA 60 mg once daily in combination with sofosbuvir for 12 weeks. The most common adverse reactions (frequency of 10% or greater) were headache and fatigue. All adverse reactions were mild to moderate in severity. One subject experienced a serious adverse event that was considered unrelated to DAKLINZA, and no subjects discontinued therapy for adverse events.</p>
                        <p>Adverse reactions considered at least possibly related to treatment and occurring at a frequency of 5% or greater are presented in Table 2.</p>
                        <table width="100%">
                           <caption>Table 2: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adverse Reactions Reported at ≥5% Frequency, DAKLINZA + Sofosbuvir for 12 Weeks</caption>
                           <colgroup><col width="49%">
                           <col width="51%">
                           </colgroup><thead>
                              <tr>
                                 <th align="left" stylecode="Botrule Toprule " valign="top">Adverse Reaction</th>
                                 <th align="center" stylecode="Botrule Toprule " valign="top">n (%) <br>n=152</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td stylecode="Toprule ">
                                    <p>Headache</p>
                                 </td>
                                 <td align="center">
                                    <p>21 (14%)</p>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <p>Fatigue</p>
                                 </td>
                                 <td align="center">
                                    <p>21 (14%)</p>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <p>Nausea</p>
                                 </td>
                                 <td align="center">
                                    <p>12 (8%)</p>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Botrule ">
                                    <p>Diarrhea</p>
                                 </td>
                                 <td align="center" stylecode="Botrule ">
                                    <p>7 (5%)</p>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text></div>
<span style="font-size : 15px; font-weight : bold;">Laboratory Abnormalities</span><div><text>
                              <p>
                                 <content stylecode="italics">Lipase Elevations: </content>Transient, asymptomatic lipase elevations of greater than 3 times the upper limit of normal (ULN) were observed in 2% of subjects in ALLY-3.</p>
                           </text></div>
<span id="DAKLINZA_collapsableElement_6_2&nbsp;" class="safetySubheading">6.2&nbsp;Postmarketing Experience</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>
                           <content stylecode="italics">Cardiac Disorders: </content>Serious symptomatic bradycardia has been reported in patients taking amiodarone who initiate treatment with sofosbuvir in combination with another HCV direct-acting antiviral, including DAKLINZA [<content stylecode="italics">see <a href="#ID_373737c1-1c3d-432d-8bc5-64cbc8867b32">Warnings and Precautions (5.2)</a> and <a href="#ID_ffe9ad53-99fb-46ee-abce-ac3fdf7343f3">Drug Interactions (7.3)</a>
                           </content>].</p>
                     </text></div>
</div>
</div>
<div class="section riskhide">
<div id="nonCollapsableElement_34073-7">
<div class="drugSubheadings">
<span id="DAKLINZA_34073-7" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>7 DRUG INTERACTIONS</div>
<div id="DAKLINZA_previewText_34073-7" class="previewText">
                        
                           
                          <span>...</span>
</div>
</div>
<div id="DAKLINZA_collapsableElement_34073-7" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                        <ul ultype="unordered">
                           <li>
                              •Drug Interactions: Coadministration of DAKLINZA can alter the concentration of other drugs and other drugs may alter the concentration of daclatasvir. Consult the full prescribing information before use for contraindicated drugs and other potential drug-drug interactions. (<a href="#ID_1afb610a-fb67-4cbc-ae78-8c69ec8773cf">2.2</a>, <a href="#ID_21aa015e-677d-4e54-b06e-cd268f43b128">4</a>, <a href="#ID_2ddbec30-4207-4015-96db-43c711ddc26f">5.1</a>, <a href="#ID_93a5ce24-f0c5-41e5-82c9-3d6cb19ade6b">7</a>, <a href="#ID_fd973a06-63f8-4471-a2de-584c0a88e03d">12.3</a>)</li>
                        </ul>
                     </text></div>
<span id="DAKLINZA_collapsableElement_7_1" class="safetySubheading">7.1 Potential for Other Drugs to Affect DAKLINZA</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>Daclatasvir is a substrate of CYP3A. Therefore, moderate or strong inducers of CYP3A may decrease the plasma levels and therapeutic effect of daclatasvir [<content stylecode="italics">see <a href="#ID_1afb610a-fb67-4cbc-ae78-8c69ec8773cf">Dosage and Administration (2.2)</a>, <a href="#ID_21aa015e-677d-4e54-b06e-cd268f43b128">Contraindications (4)</a>, and Table 3</content>]. Strong inhibitors of CYP3A (eg, clarithromycin, itraconazole, ketoconazole, ritonavir) may increase the plasma levels of daclatasvir [<content stylecode="italics">see <a href="#ID_1afb610a-fb67-4cbc-ae78-8c69ec8773cf">Dosage and Administration (2.2)</a> and Table 3</content>].</p>
                     </text></div>
<span id="DAKLINZA_collapsableElement_7_2" class="safetySubheading">7.2 Potential for DAKLINZA to Affect Other Drugs</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>Daclatasvir is an inhibitor of P-glycoprotein transporter (P-gp), organic anion transporting polypeptide (OATP) 1B1 and 1B3, and breast cancer resistance protein (BCRP). Administration of DAKLINZA may increase systemic exposure to medicinal products that are substrates of P-gp, OATP 1B1 or 1B3, or BCRP, which could increase or prolong their therapeutic effect or adverse reactions (<content stylecode="italics">see Table 3</content>).</p>
                     </text></div>
<span id="DAKLINZA_collapsableElement_7_3" class="safetySubheading">7.3 Established and Potentially Significant Drug Interactions</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>Refer to the prescribing information for sofosbuvir for drug interaction information. The most conservative recommendation should be followed.</p>
                        <p>Table 3 provides clinical recommendations for established or potentially significant drug interactions between DAKLINZA and other drugs [<content stylecode="italics">see <a href="#ID_21aa015e-677d-4e54-b06e-cd268f43b128">Contraindications (4)</a>
                           </content>]. Clinically relevant increase in concentration is indicated as “↑” and clinically relevant decrease as “↓” [for drug interaction data, <content stylecode="italics">see <a href="#ID_fd973a06-63f8-4471-a2de-584c0a88e03d">Clinical Pharmacology (12.3)</a>
                           </content>].</p>
                        <table id="_Ref381622093" width="100%">
                           <caption>Table 3:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Established and Other Potentially Significant Drug Interactions</caption>
                           <colgroup><col width="33%">
                           <col width="17%">
                           <col width="50%">
                           </colgroup><thead>
                              <tr>
                                 <th align="left" stylecode="Rrule Botrule Toprule " valign="top">
                                    <content stylecode="bold">Concomitant Drug Class:<br>Drug Name</content>
                                 </th>
                                 <th align="center" stylecode="Rrule Botrule Lrule Toprule " valign="top">
                                    <content stylecode="bold">Effect on Concentration<sup>a</sup>
                                    </content>
                                 </th>
                                 <th align="center" stylecode="Botrule Lrule Toprule " valign="top">
                                    <content stylecode="bold">Clinical Comment</content>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" stylecode="Botrule" valign="top">
                                    <sup>a</sup>&nbsp;&nbsp;&nbsp;The direction of the arrow (↑ = increase, ↓ = decrease) indicates the direction of the change in pharmacokinetic parameters.<br>
                                    <sup>b</sup>&nbsp;&nbsp;&nbsp;These interactions have been studied [<content stylecode="emphasis">
                                       <content stylecode="italics">see <a href="#ID_fd973a06-63f8-4471-a2de-584c0a88e03d">Clinical Pharmacology (12.3</a>, Tables 5 and 6)</content>
                                    </content>].</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td stylecode="Toprule Botrule ">
                                    <p>
                                       <content stylecode="italics">Strong CYP3A inhibitors</content>
                                    </p>
                                 </td>
                                 <td stylecode="Toprule Botrule "></td>
                                 <td stylecode="Toprule Botrule "></td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Toprule Botrule ">
                                    <p>Examples: atazanavir/ritonavir,<sup>b</sup> clarithromycin, indinavir, itraconazole, ketoconazole,<sup>b</sup> nefazodone, nelfinavir, posaconazole, saquinavir, telithromycin, voriconazole</p>
                                 </td>
                                 <td align="center" stylecode="Rrule Lrule Toprule Botrule ">
                                    <p>↑ Daclatasvir</p>
                                 </td>
                                 <td stylecode="Lrule Toprule Botrule ">
                                    <p>Decrease DAKLINZA dose to 30&nbsp;mg once daily when coadministered with strong inhibitors of CYP3A.</p>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule ">
                                    <p>
                                       <content stylecode="italics">Moderate CYP3A inhibitors</content>
                                    </p>
                                 </td>
                                 <td stylecode="Toprule Botrule "></td>
                                 <td stylecode="Toprule Botrule "></td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Toprule Botrule ">
                                    <p>Examples: atazanavir, ciprofloxacin, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, verapamil</p>
                                 </td>
                                 <td align="center" stylecode="Rrule Lrule Toprule Botrule ">
                                    <p>↑ Daclatasvir</p>
                                 </td>
                                 <td stylecode="Lrule Toprule Botrule ">
                                    <p>Monitor for daclatasvir adverse events.</p>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule ">
                                    <p>
                                       <content stylecode="italics">Moderate CYP3A inducers</content>
                                    </p>
                                 </td>
                                 <td stylecode="Toprule Botrule "></td>
                                 <td stylecode="Toprule Botrule "></td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Toprule Botrule ">
                                    <p>Examples:  bosentan, dexamethasone, efavirenz,<sup>b</sup> etravirine, modafinil, nafcillin, rifapentine</p>
                                 </td>
                                 <td align="center" stylecode="Rrule Lrule Toprule Botrule ">
                                    <p>↓ Daclatasvir</p>
                                 </td>
                                 <td stylecode="Lrule Toprule Botrule ">
                                    <p>Increase DAKLINZA dose to 90 mg once daily when coadministered with moderate inducers of CYP3A.</p>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule ">
                                    <p>
                                       <content stylecode="italics">Anticoagulants</content>
                                    </p>
                                 </td>
                                 <td stylecode="Toprule Botrule "></td>
                                 <td stylecode="Toprule Botrule "></td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Toprule Botrule ">
                                    <p>Dabigatran etexilate mesylate</p>
                                 </td>
                                 <td align="center" stylecode="Rrule Lrule Toprule Botrule ">
                                    <p>↑ Dabigatran</p>
                                 </td>
                                 <td stylecode="Lrule Toprule Botrule ">
                                    <p>Use of DAKLINZA with dabigatran etexilate is not recommended in specific renal impairment groups, depending on the indication. Please see the dabigatran prescribing information for specific recommendations.</p>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule ">
                                    <p>
                                       <content stylecode="italics">Cardiovascular agents</content>
                                    </p>
                                 </td>
                                 <td stylecode="Toprule Botrule "></td>
                                 <td stylecode="Toprule Botrule "></td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Toprule Botrule ">
                                    <p>Antiarrhythmic:<br>&nbsp;&nbsp;&nbsp;Amiodarone</p>
                                 </td>
                                 <td align="center" stylecode="Rrule Lrule Toprule Botrule ">
                                    <p>
                                       <br>Amiodarone: effects unknown</p>
                                 </td>
                                 <td stylecode="Lrule Toprule Botrule ">
                                    <p>
                                       <br>Coadministration of amiodarone with DAKLINZA in combination with sofosbuvir is not recommended because it may result in serious symptomatic bradycardia. The mechanism of this effect is unknown. If coadministration is required, cardiac monitoring is recommended. [<content stylecode="italics">See <a href="#ID_373737c1-1c3d-432d-8bc5-64cbc8867b32">Warnings and Precautions (5.2)</a> and <a href="#ID_4225c82a-ae5b-4b78-82ce-dcbff5089df5">Adverse Reactions (6.2)</a>.</content>]</p>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Toprule Botrule ">
                                    <p>Antiarrhythmic:<br>&nbsp;&nbsp;&nbsp;Digoxin<sup>b</sup>
                                    </p>
                                 </td>
                                 <td align="center" stylecode="Rrule Lrule Toprule Botrule ">
                                    <p>
                                       <br>↑ Digoxin</p>
                                 </td>
                                 <td stylecode="Lrule Toprule Botrule ">
                                    <p>
                                       <br>
                                       <content stylecode="underline">Patients already receiving daclatasvir initiating digoxin</content>: Initiate treatment using the lowest appropriate digoxin dosage. Monitor digoxin concentrations; adjust digoxin doses if necessary and continue monitoring.</p>
                                    <p>&nbsp;</p>
                                    <p>
                                       <content stylecode="underline">Patients already receiving digoxin prior to initiating daclatasvir</content>: Measure serum digoxin concentrations before initiating daclatasvir. Reduce digoxin concentrations by decreasing digoxin dosage by approximately 30% to 50% or by modifying the dosing frequency and continue monitoring.</p>
                                 </td>
                              </tr>
                              <tr>
                                 <td stylecode="Toprule Botrule ">
                                    <p>
                                       <content stylecode="italics">Lipid-lowering agents</content>
                                    </p>
                                 </td>
                                 <td stylecode="Toprule Botrule "></td>
                                 <td stylecode="Toprule Botrule "></td>
                              </tr>
                              <tr>
                                 <td stylecode="Rrule Botrule Toprule ">
                                    <p>HMG-CoA reductase inhibitors:<br>&nbsp;&nbsp;&nbsp;Atorvastatin<br>&nbsp;&nbsp;&nbsp;Fluvastatin<br>&nbsp;&nbsp;&nbsp;Pitavastatin<br>&nbsp;&nbsp;&nbsp;Pravastatin</p>
                                    <p>&nbsp;&nbsp;&nbsp;Rosuvastatin<sup>b</sup>
                                       <br>&nbsp;&nbsp;&nbsp;Simvastatin</p>
                                 </td>
                                 <td align="center" stylecode="Rrule Botrule Lrule Toprule ">
                                    <p>
                                       <br>↑ Atorvastatin<br>↑ Fluvastatin<br>↑ Pitavastatin<br>↑ Pravastatin<br>↑ Rosuvastatin<br>↑ Simvastatin</p>
                                 </td>
                                 <td stylecode="Botrule Lrule Toprule ">
                                    <p>
                                       <br>Monitor for HMG-CoA reductase inhibitor associated adverse events such as myopathy.</p>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text></div>
<span id="DAKLINZA_collapsableElement_7_4" class="safetySubheading">7.4 Drugs without Clinically Significant Interactions with DAKLINZA</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>Based on the results of drug interaction trials [<content stylecode="italics">see <a href="#ID_fd973a06-63f8-4471-a2de-584c0a88e03d">Clinical Pharmacology (12.3)</a>
                           </content>], no clinically relevant changes in exposure were observed for cyclosporine, escitalopram, ethinyl estradiol/norgestimate, methadone, midazolam, tacrolimus, or tenofovir with concomitant use of daclatasvir. No clinically relevant changes in daclatasvir exposure were observed with cyclosporine, escitalopram, famotidine, omeprazole, sofosbuvir, tacrolimus, or tenofovir. No clinically relevant interaction is anticipated for daclatasvir or the following concomitant medications: peginterferon alfa, ribavirin, or antacids.</p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_43684-0">
<div class="drugSubheadings">
<span id="DAKLINZA_43684-0" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>8 USE IN SPECIFIC POPULATIONS</div>
<div id="DAKLINZA_previewText_43684-0" class="previewText"><span>...</span></div>
</div>
<div id="DAKLINZA_collapsableElement_43684-0" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"></div>
<span id="DAKLINZA_collapsableElement_8_1" class="safetySubheading">8.1 Pregnancy</span><div id="42228-7" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;">Risk Summary</span><div><text>
                              <p>No data with DAKLINZA in pregnant women are available to inform a drug-associated risk. In animal reproduction studies in rats and rabbits, no evidence of fetal harm was observed with oral administration of daclatasvir during organogenesis at doses that produced exposures up to 6 and 22 times, respectively, the recommended human dose (RHD) of 60 mg. However, embryofetal toxicity was observed in rats and rabbits at maternally toxic doses that produced exposures of 33 and 98 times the human exposure, respectively, at the RHD of 60 mg [<content stylecode="italics">see <a href="#ID_c0b217ec-979c-426a-ae49-f2decce621c5">Data</a>
                                 </content>]. Consider the benefits and risks of DAKLINZA when prescribing DAKLINZA to a pregnant woman.</p>
                              <p>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;">Data</span><div></div>
<span id="DAKLINZA_collapsableElement_8_2&nbsp;" class="safetySubheading">8.2&nbsp;Lactation</span><div id="42229-5" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;">Risk Summary</span><div><text>
                              <p>No information regarding the presence of daclatasvir in human milk, the effects on the breastfed infant, or the effects on milk production is available. Daclatasvir is present in the milk of lactating rats [<content stylecode="italics">see <a href="#ID_0de36119-2a70-4b67-b994-0166761b8ee8">Use in Specific Populations (8.1</a>)</content>]. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for DAKLINZA and any potential adverse effects on the breastfed infant from DAKLINZA or from the underlying maternal condition.</p>
                           </text></div>
<span id="DAKLINZA_collapsableElement_8_4" class="safetySubheading">8.4 Pediatric Use</span><div id="34081-0" class="safetySubdescription"><text>
                        <p>Safety and effectiveness of DAKLINZA in pediatric patients younger than 18 years of age have not been established.</p>
                     </text></div>
<span id="DAKLINZA_collapsableElement_8_5" class="safetySubheading">8.5 Geriatric Use</span><div id="34082-8" class="safetySubdescription"><text>
                        <p>Safety was similar across older and younger subjects and there were no safety findings unique to subjects 65 years and older. Sustained virologic response (SVR) rates were comparable among older and younger subjects. No dosage adjustment of DAKLINZA is required for elderly patients [<content stylecode="italics">see <a href="#ID_fd973a06-63f8-4471-a2de-584c0a88e03d">Clinical Pharmacology (12.3)</a>
                           </content>].</p>
                     </text></div>
<span id="DAKLINZA_collapsableElement_8_6" class="safetySubheading">8.6 Renal Impairment</span><div id="43684-0" class="safetySubdescription"><text>
                        <p>No dosage adjustment of DAKLINZA is required for patients with any degree of renal impairment [<content stylecode="italics">see </content>
                           <content stylecode="italics">
                              <a href="#ID_fd973a06-63f8-4471-a2de-584c0a88e03d">Clinical Pharmacology (12.3)</a>
                           </content>].</p>
                     </text></div>
<span id="DAKLINZA_collapsableElement_8_7" class="safetySubheading">8.7 Hepatic Impairment</span><div id="43684-0" class="safetySubdescription"><text>
                        <p>No dosage adjustment of DAKLINZA is required for patients with mild (Child-Pugh A), moderate (Child-Pugh B), or severe (Child-Pugh C) hepatic impairment [<content stylecode="italics">see </content>
                           <content stylecode="italics">
                              <a href="#ID_fd973a06-63f8-4471-a2de-584c0a88e03d">Clinical Pharmacology (12.3)</a>
                           </content>]. Safety and efficacy of DAKLINZA have not been established in patients with decompensated cirrhosis.</p>
                     </text></div>
<span id="DAKLINZA_collapsableElement_8_8" class="safetySubheading">8.8 Liver Transplant Patients</span><div id="43684-0" class="safetySubdescription"><text>
                        <p>The safety and efficacy of DAKLINZA combination therapy have not been established in liver transplant patients.</p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34088-5">
<div class="drugSubheadings">
<span id="DAKLINZA_34088-5" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>10 OVERDOSAGE</div>
<div id="DAKLINZA_previewText_34088-5" class="previewText">
                  There is no known antidote for overdose of DAKLINZA. Treatmen<span>...</span>
</div>
</div>
<div id="DAKLINZA_collapsableElement_34088-5" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"><text>
                  <p>There is no known antidote for overdose of DAKLINZA. Treatment of overdose with DAKLINZA should consist of general supportive measures, including monitoring of vital signs and observation of the patient’s clinical status. Because daclatasvir is highly protein bound (&gt;99%), dialysis is unlikely to significantly reduce plasma concentrations of the drug.</p>
               </text></div></div>
</div>
<div class="section">
<div id="nonCollapsableElement_34089-3">
<div class="drugSubheadings">
<span id="DAKLINZA_34089-3" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>11 DESCRIPTION</div>
<div id="DAKLINZA_previewText_34089-3" class="previewText">
                  DAKLINZA (daclatasvir) is an inhibitor of HCV nonstructural p<span>...</span>
</div>
</div>
<div id="DAKLINZA_collapsableElement_34089-3" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                  <p>DAKLINZA (daclatasvir) is an inhibitor of HCV nonstructural protein 5A (NS5A). The chemical name for drug substance daclatasvir dihydrochloride is carbamic acid,<content stylecode="italics"> N</content>,<content stylecode="italics">N</content>′-[[1,1′-biphenyl]-4,4′-diylbis[1<content stylecode="italics">H</content>-imidazole-5,2-diyl-(2<content stylecode="italics">S</content>)-2,1-pyrrolidinediyl[(1<content stylecode="italics">S</content>)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, <content stylecode="italics">C</content>,<content stylecode="italics">C</content>′-dimethyl ester, hydrochloride (1:2). Its molecular formula is C<sub>40</sub>H<sub>50</sub>N<sub>8</sub>O<sub>6</sub>•2HCl, and its molecular weight is 738.88 (free base). Daclatasvir dihydrochloride has the following structural formula:</p>
                  <rendermultimedia id="id19552058" referencedobject="AEA32949-53A8-4924-92AD-26E18EAFC432"></rendermultimedia>
                  <p>Daclatasvir dihydrochloride drug substance is white to yellow. Daclatasvir is freely soluble in water (&gt;700 mg/mL).</p>
                  <p>DAKLINZA 60 mg tablets contain 60 mg daclatasvir (equivalent to 66 mg daclatasvir dihydrochloride) and the inactive ingredients anhydrous lactose (116 mg), microcrystalline cellulose, croscarmellose sodium, silicon dioxide, magnesium stearate, and Opadry green. DAKLINZA 30 mg tablets contain 30 mg daclatasvir (equivalent to 33 mg daclatasvir dihydrochloride) and the inactive ingredients anhydrous lactose (58 mg), microcrystalline cellulose, croscarmellose sodium, silicon dioxide, magnesium stearate, and Opadry green. Opadry green contains hypromellose, titanium dioxide, polyethylene glycol 400, FD&amp;C blue #2/indigo carmine aluminum lake, and yellow iron oxide.</p>
               </text></div>
<span id="DAKLINZA_collapsableElement_" class="safetySubheading"></span><div id="" class="safetySubdescription"></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34090-1">
<div class="drugSubheadings">
<span id="DAKLINZA_34090-1" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>12 CLINICAL PHARMACOLOGY</div>
<div id="DAKLINZA_previewText_34090-1" class="previewText"><span>...</span></div>
</div>
<div id="DAKLINZA_collapsableElement_34090-1" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"></div>
<span id="DAKLINZA_collapsableElement_12_1" class="safetySubheading">12.1 Mechanism of Action</span><div id="43679-0" class="safetySubdescription"><text>
                        <p>Daclatasvir is a direct-acting antiviral agent (DAA) against the hepatitis C virus [<content stylecode="italics">see <a href="#ID_c9493748-799b-4e72-987d-8e39e85ead8c">Microbiology (12.4)</a>
                           </content>].</p>
                     </text></div>
<span id="DAKLINZA_collapsableElement_12_2" class="safetySubheading">12.2 Pharmacodynamics</span><div id="43681-6" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;">Cardiac Electrophysiology</span><div><text>
                              <p>At a dose 3 times the maximum recommended dose, daclatasvir does not prolong the QT interval to any clinically relevant extent.</p>
                           </text></div>
<span id="DAKLINZA_collapsableElement_12_3" class="safetySubheading">12.3 Pharmacokinetics</span><div id="43682-4" class="safetySubdescription"><text>
                        <p>The pharmacokinetic properties of daclatasvir were evaluated in healthy adult subjects and in subjects with chronic HCV. Administration of daclatasvir tablets in HCV-infected subjects resulted in approximately dose-proportional increases in C<sub>max</sub>, AUC, and C<sub>min </sub>up to 60 mg once daily. Steady state is anticipated after approximately 4 days of once-daily daclatasvir administration. Exposure of daclatasvir was similar between healthy and HCV-infected subjects. Population pharmacokinetic estimates for daclatasvir 60 mg once daily in chronic HCV-infected subjects are shown in Table 4.</p>
                        <table width="100%">
                           <caption>Table 4:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Population Pharmacokinetic Estimates for Daclatasvir in Chronic HCV-Infected Subjects Receiving Daclatasvir&nbsp;60 mg Once Daily and Sofosbuvir 400 mg Once Daily</caption>
                           <colgroup><col width="50%">
                           <col width="50%">
                           </colgroup><thead>
                              <tr>
                                 <th align="left" stylecode="Rrule Botrule Toprule " valign="top">Parameters</th>
                                 <th align="center" stylecode="Botrule Lrule Toprule " valign="top">
                                    <content stylecode="bold">Daclatasvir 60 mg once daily<br>(n=152)</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="left" stylecode="Rrule Toprule ">
                                    <p>AUC<sub>0-24h</sub> (ng•h/mL)</p>
                                 </td>
                                 <td stylecode="Lrule "></td>
                              </tr>
                              <tr>
                                 <td align="left" stylecode="Rrule ">
                                    <p>&nbsp;&nbsp;&nbsp;Mean ± standard deviation </p>
                                 </td>
                                 <td align="center" stylecode="Lrule ">
                                    <p>10973 ± 5288</p>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" stylecode="Rrule Botrule ">
                                    <p>&nbsp;&nbsp;&nbsp;Median (range) </p>
                                 </td>
                                 <td align="center" stylecode="Lrule Botrule ">
                                    <p>9680 (3807-41243)</p>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" stylecode="Rrule Toprule ">
                                    <p>C<sub>24h</sub> (ng/mL)</p>
                                 </td>
                                 <td stylecode="Lrule Toprule "></td>
                              </tr>
                              <tr>
                                 <td align="left" stylecode="Rrule ">
                                    <p>&nbsp;&nbsp;&nbsp;Mean ± standard deviation</p>
                                 </td>
                                 <td align="center" stylecode="Lrule ">
                                    <p>182 ± 137</p>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" stylecode="Rrule Botrule ">
                                    <p>&nbsp;&nbsp;&nbsp;Median (range)</p>
                                 </td>
                                 <td align="center" stylecode="Botrule Lrule ">
                                    <p>148 (21-1050)</p>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text></div>
<span style="font-size : 15px; font-weight : bold;">Absorption and Bioavailability</span><div><text>
                              <p>In HCV-infected subjects following multiple oral doses of daclatasvir tablet ranging from 1 mg to 100 mg once daily, peak plasma concentrations occurred within 2 hours post dose.</p>
                              <p>
                                 <content stylecode="italics">In vitro</content> studies with human Caco-2 cells indicated that daclatasvir is a substrate of P-gp. The absolute bioavailability of the tablet formulation is 67%.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;">Effect of Food on Oral Absorption</span><div><text>
                              <p>In healthy subjects, administration of a daclatasvir 60 mg tablet after a high-fat, high-caloric meal (approximately 951 total kcal, 492 kcal from fat, 312 kcal from carbohydrates, 144 kcal from protein) decreased daclatasvir C<sub>max</sub> and AUC<sub>(0-inf)</sub> by 28% and 23%, respectively, compared with fasted conditions. A food effect was not observed with administration of a daclatasvir 60 mg tablet after a low-fat, low-caloric meal (approximately 277 total kcal, 41 kcal from fat, 190 kcal from carbohydrates, 44 kcal from protein) compared with fasted conditions [<content stylecode="italics">see <a href="#ID_f811910c-7da4-42e0-b693-0db6ceeb64ca">Dosage and Administration (2)</a>
                                 </content>].</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;">Distribution</span><div><text>
                              <p>With multiple dosing, protein binding of daclatasvir in HCV-infected subjects was approximately 99% and independent of dose at the dose range studied (1-100 mg). In subjects who received daclatasvir 60 mg tablet orally followed by 100 μg [<sup>13</sup>C,<sup>15</sup>N]-daclatasvir intravenous dose, estimated volume of distribution at steady state was 47 L.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;">Metabolism</span><div><text>
                              <p>Daclatasvir is a substrate of CYP3A, with CYP3A4 being the primary CYP isoform responsible for metabolism. Following single-dose oral administration of 25 mg <sup>14</sup>C-daclatasvir in healthy subjects, the majority of radioactivity in plasma was predominately attributed to parent drug (97% or greater).</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;">Elimination</span><div><text>
                              <p>Following single-dose oral administration of 25 mg <sup>14</sup>C-daclatasvir in healthy subjects, 88% of total radioactivity was recovered in feces (53% of the dose as unchanged daclatasvir) and 6.6% of the dose was excreted in the urine (primarily as unchanged daclatasvir). Following multiple-dose administration of daclatasvir in HCV-infected subjects, with doses ranging from 1 mg to 100 mg once daily, the terminal elimination half-life of daclatasvir ranged from approximately 12 to 15 hours. In subjects who received daclatasvir 60 mg tablet orally followed by 100 μg [<sup>13</sup>C,<sup>15</sup>N]-daclatasvir intravenous dose, the total clearance was 4.2 L/h.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;">Specific Populations</span><div></div>
<span style="font-size : 15px; font-weight : bold;">Drug Interactions</span><div></div>
<span id="DAKLINZA_collapsableElement_12_4" class="safetySubheading">12.4 Microbiology</span><div id="49489-8" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;">Mechanism of Action</span><div><text>
                              <p>Daclatasvir is an inhibitor of NS5A, a nonstructural protein encoded by HCV. Daclatasvir binds to the N-terminus of NS5A and inhibits both viral RNA replication and virion assembly. Characterization of daclatasvir-resistant viruses, biochemical studies, and computer modeling data indicate that daclatasvir interacts with the N-terminus within Domain 1 of the protein, which may cause structural distortions that interfere with NS5A functions.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;">Antiviral Activity</span><div><text>
                              <p>Daclatasvir had a median EC<sub>50</sub> value of 0.2 nM (range, 0.006-3.2 nM, n=17) against hybrid replicons containing genotype 3a subject-derived NS5A sequences without detectable daclatasvir resistance-associated polymorphisms at NS5A amino acid positions 28, 30, 31, or 93. Daclatasvir activity was reduced against genotype 3a subject-derived replicons with resistance-associated polymorphisms at positions 28, 30, 31, or 93, with a median EC<sub>50</sub> value of 13.5 nM (range, 1.3-50 nM). Similarly, the EC<sub>50</sub> values of daclatasvir against 3 genotype 3b and 1 genotype 3i subject-derived NS5A sequences with polymorphisms (relative to a genotype 3a reference) at positions 30 or 31 were ≥3620 nM.</p>
                              <p>The median EC<sub>50</sub> values of daclatasvir for genotypes 1a, 1b, 2, 4, and 5 subject-derived NS5A hybrid replicons were 0.008 nM (range, 0.002-2409 nM, n=40), 0.002 nM (range, 0.0007-10 nM, n=42), 16 nM (range, 0.005-60 nM, n=16), 0.025 nM (range, 0.001-158 nM, n=14), and 0.004&nbsp;nM (range, 0.003-0.019 nM, n=3), respectively. The EC<sub>50</sub> value against a single HCV genotype 6 derived replicon was 0.054 nM.</p>
                              <p>Daclatasvir was not antagonistic with interferon alfa, HCV NS3/4A protease inhibitors, HCV NS5B nucleoside analog inhibitors, and HCV NS5B non-nucleoside inhibitors in cell culture combination antiviral activity studies using the cell-based HCV replicon system.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;">Resistance</span><div></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_43680-8">
<div class="drugSubheadings">
<span id="DAKLINZA_43680-8" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>13 NONCLINICAL TOXICOLOGY</div>
<div id="DAKLINZA_previewText_43680-8" class="previewText"><span>...</span></div>
</div>
<div id="DAKLINZA_collapsableElement_43680-8" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"></div>
<span id="DAKLINZA_collapsableElement_13_1" class="safetySubheading">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</span><div id="34083-6" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;">Carcinogenesis and Mutagenesis</span><div><text>
                              <p>A 2-year carcinogenicity study in Sprague Dawley rats and a 6-month study in transgenic (Tg rasH2) mice were conducted with daclatasvir. In the 2-year study in rats, no drug-related increase in tumor incidence was observed at doses up to 50 mg/kg/day (both sexes). Daclatasvir exposures at these doses were approximately 6-fold (males and females) the human systemic exposure at the therapeutic daily dose. In transgenic mice no drug-related increase in tumor incidence was observed at doses of 300 mg/kg/day (both sexes).</p>
                              <p>Daclatasvir was not genotoxic in a battery of <content stylecode="italics">in vitro </content>or <content stylecode="italics">in vivo </content>assays, including bacterial mutagenicity (Ames) assays, mammalian mutation assays in Chinese hamster ovary cells, or in an <content stylecode="italics">in vivo</content> oral micronucleus study in rats.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;">Impairment of Fertility</span><div><text>
                              <p>Daclatasvir had no effects on fertility in female rats at any dose tested. Daclatasvir exposures at these doses in females were approximately 24-fold the human systemic exposure at the therapeutic daily dose. In male rats, effects on reproductive endpoints at 200 mg/kg/day included reduced prostate/seminal vesicle weights, minimally increased dysmorphic sperm, as well as increased mean pre-implantation loss in litters sired by treated males. Daclatasvir exposures at the 200 mg/kg/day dose in males were approximately 26-fold the human systemic exposure at the therapeutic daily dose. Exposures at 50 mg/kg/day in males produced no notable effects and was 4.7-fold the exposure in humans at the recommended daily dose.</p>
                           </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34092-7">
<div class="drugSubheadings">
<span id="DAKLINZA_34092-7" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>14 CLINICAL STUDIES</div>
<div id="DAKLINZA_previewText_34092-7" class="previewText">
                  The efficacy and safety of DAKLINZA in combination with sofos<span>...</span>
</div>
</div>
<div id="DAKLINZA_collapsableElement_34092-7" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"><text>
                  <p>The efficacy and safety of DAKLINZA in combination with sofosbuvir were evaluated in the phase 3 ALLY-3 (AI444-218) clinical trial. ALLY-3 was an open-label trial that included 152 subjects with chronic HCV genotype 3 infection and compensated liver disease who were treatment-naive (n=101) or treatment-experienced (n=51). Most treatment-experienced subjects had failed prior treatment with peginterferon/ribavirin, but 7 subjects had been treated previously with a sofosbuvir regimen and 2 subjects with a regimen containing an investigational cyclophilin inhibitor. Previous exposure to NS5A inhibitors was prohibited. Subjects received DAKLINZA 60 mg plus sofosbuvir 400 mg once daily for 12 weeks and were monitored for 24 weeks post treatment. HCV RNA values were measured during the clinical trial using the COBAS<sup>®</sup> TaqMan<sup>®</sup> HCV test (version 2.0), for use with the High Pure System. The assay had a lower limit of quantification (LLOQ) of 25 IU per mL. Sustained virologic response (SVR) was the primary endpoint and was defined as HCV RNA below the LLOQ at post-treatment week 12 (SVR12).</p>
                  <p>The 152 treated subjects in ALLY-3 had a median age of 55 years (range, 24-73); 59% of the subjects were male; 90% were white, 5% were Asian, and 4% were black. Most subjects (76%) had baseline HCV RNA levels greater than or equal to 800,000 IU/mL; 21% of the subjects had compensated cirrhosis, and 40% had the IL28B rs12979860 CC genotype.</p>
                  <p>SVR and outcomes in subjects without SVR in ALLY-3 are shown by patient population in Table 8. For SVR outcomes related to the baseline NS5A Y93H polymorphism, see <content stylecode="italics">Microbiology (12.4)</content>. SVR rates were comparable regardless of age, gender, IL28B allele status, or baseline HCV RNA level.</p>
                  <table width="100%">
                     <caption>Table 8:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment Outcomes in ALLY-3: DAKLINZA in Combination with Sofosbuvir in Subjects with HCV Genotype 3 Infection</caption>
                     <colgroup><col width="35%">
                     <col width="20%">
                     <col width="23%">
                     <col width="22%">
                     </colgroup><thead>
                        <tr>
                           <th align="left" stylecode="Rrule Botrule Toprule " valign="top">Treatment Outcomes</th>
                           <th align="center" stylecode="Rrule Botrule Lrule Toprule " valign="top">Treatment-Naive<br>n=101</th>
                           <th align="center" stylecode="Rrule Botrule Lrule Toprule " valign="top">Treatment-Experienced<br>n=51</th>
                           <th align="center" stylecode="Botrule Lrule Toprule " valign="top">Total<br>n=152</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="4" stylecode="Botrule" valign="top">
                              <sup>a</sup>&nbsp;&nbsp;&nbsp;Includes 11 subjects with missing or inconclusive cirrhosis status.<br>
                              <sup>b</sup>&nbsp;&nbsp;&nbsp;One subject had quantifiable HCV RNA at end of treatment.<br>
                              <sup>c</sup>&nbsp;&nbsp;&nbsp;Relapse rates are calculated with a denominator of subjects with HCV RNA not detected at the end of treatment.</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td stylecode="Rrule Toprule ">
                              <p>
                                 <content stylecode="bold">SVR</content>
                                 <br>All</p>
                           </td>
                           <td align="center" stylecode="Rrule Lrule Toprule ">
                              <p>
                                 <br>90% (91/101)</p>
                           </td>
                           <td align="center" stylecode="Rrule Lrule Toprule ">
                              <p>
                                 <br>86% (44/51)</p>
                           </td>
                           <td align="center" stylecode="Lrule Toprule ">
                              <p>
                                 <br>89% (135/152)</p>
                           </td>
                        </tr>
                        <tr>
                           <td stylecode="Rrule ">
                              <p>&nbsp;&nbsp;&nbsp;No cirrhosis<sup>a</sup>
                              </p>
                           </td>
                           <td align="center" stylecode="Rrule Lrule ">
                              <p>98% (80/82)</p>
                           </td>
                           <td align="center" stylecode="Rrule Lrule ">
                              <p>92% (35/38)</p>
                           </td>
                           <td align="center" stylecode="Lrule ">
                              <p>96% (115/120)</p>
                           </td>
                        </tr>
                        <tr>
                           <td stylecode="Rrule Botrule ">
                              <p>&nbsp;&nbsp;&nbsp;With cirrhosis</p>
                           </td>
                           <td align="center" stylecode="Rrule Lrule Botrule ">
                              <p>58% (11/19)</p>
                           </td>
                           <td align="center" stylecode="Rrule Lrule Botrule ">
                              <p>69% (9/13)</p>
                           </td>
                           <td align="center" stylecode="Lrule Botrule ">
                              <p>63% (20/32)</p>
                           </td>
                        </tr>
                        <tr>
                           <td stylecode="Rrule Toprule ">
                              <p>
                                 <content stylecode="bold">Outcomes for subjects without SVR</content>
                              </p>
                           </td>
                           <td stylecode="Rrule Lrule Toprule "></td>
                           <td stylecode="Rrule Lrule Toprule "></td>
                           <td stylecode="Lrule Toprule "></td>
                        </tr>
                        <tr>
                           <td stylecode="Rrule ">
                              <p>&nbsp;&nbsp;&nbsp;On-treatment virologic failure<sup>b</sup>
                              </p>
                           </td>
                           <td align="center" stylecode="Rrule Lrule ">
                              <p>1% (1/101)</p>
                           </td>
                           <td align="center" stylecode="Rrule Lrule ">
                              <p>0</p>
                           </td>
                           <td align="center" stylecode="Lrule ">
                              <p>0.7% (1/152)</p>
                           </td>
                        </tr>
                        <tr>
                           <td stylecode="Rrule Botrule ">
                              <p>&nbsp;&nbsp;&nbsp;Relapse<sup>c</sup>
                              </p>
                           </td>
                           <td align="center" stylecode="Rrule Botrule Lrule ">
                              <p>9% (9/100)</p>
                           </td>
                           <td align="center" stylecode="Rrule Botrule Lrule ">
                              <p>14% (7/51)</p>
                           </td>
                           <td align="center" stylecode="Botrule Lrule ">
                              <p>11% (16/151)</p>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text></div></div>
</div>
<div class="section">
<div id="nonCollapsableElement_34069-5">
<div class="drugSubheadings">
<span id="DAKLINZA_34069-5" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>16 HOW SUPPLIED/STORAGE AND HANDLING</div>
<div id="DAKLINZA_previewText_34069-5" class="previewText"><span>...</span></div>
</div>
<div id="DAKLINZA_collapsableElement_34069-5" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"></div>
<span id="DAKLINZA_collapsableElement_16_1" class="safetySubheading">16.1 How Supplied</span><div id="42229-5" class="safetySubdescription"><text>
                        <p>DAKLINZA is packaged in bottles as described in the table.</p>
                        <table width="100%">
                           <colgroup><col width="12%">
                           <col width="20%">
                           <col width="36%">
                           <col width="16%">
                           <col width="16%">
                           </colgroup><tbody>
                              <tr>
                                 <td align="center" stylecode="Botrule ">
                                    <p>
                                       <content stylecode="bold">Tablet Strength</content>
                                    </p>
                                 </td>
                                 <td align="center" stylecode="Botrule ">
                                    <p>
                                       <content stylecode="bold">Tablet Color/Shape</content>
                                    </p>
                                 </td>
                                 <td align="center" stylecode="Botrule ">
                                    <p>
                                       <content stylecode="bold">Tablet Markings</content>
                                    </p>
                                 </td>
                                 <td align="center" stylecode="Botrule ">
                                    <p>
                                       <content stylecode="bold">Package Size</content>
                                    </p>
                                 </td>
                                 <td align="center" stylecode="Botrule ">
                                    <p>
                                       <content stylecode="bold">NDC Code</content>
                                    </p>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" stylecode="Toprule Botrule ">
                                    <p>60 mg</p>
                                 </td>
                                 <td stylecode="Toprule Botrule ">
                                    <p>Light green, biconvex, pentagonal</p>
                                 </td>
                                 <td stylecode="Toprule Botrule ">
                                    <p>Debossed with “BMS” on one side and “215” on the other side</p>
                                 </td>
                                 <td align="center" stylecode="Toprule Botrule ">
                                    <p>Bottles of 28</p>
                                 </td>
                                 <td align="center" stylecode="Toprule Botrule ">
                                    <p>0003-0215-01</p>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" stylecode="Botrule Toprule ">
                                    <p>30 mg</p>
                                 </td>
                                 <td stylecode="Botrule Toprule ">
                                    <p>Green, biconvex, pentagonal</p>
                                 </td>
                                 <td stylecode="Botrule Toprule ">
                                    <p>Debossed with “BMS” on one side and “213” on the other side</p>
                                 </td>
                                 <td align="center" stylecode="Botrule Toprule ">
                                    <p>Bottles of 28</p>
                                 </td>
                                 <td align="center" stylecode="Botrule Toprule ">
                                    <p>0003-0213-01</p>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text></div>
<span id="DAKLINZA_collapsableElement_16_2" class="safetySubheading">16.2 Storage</span><div id="44425-7" class="safetySubdescription"><text>
                        <p>Store DAKLINZA tablets at 25°C (77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].</p>
                     </text></div>
</div>
</div>
<div class="section">
<div id="nonCollapsableElement_34076-0">
<div class="drugSubheadings">
<span id="DAKLINZA_34076-0" class="drug-label-close" onclick="Template.Safety.toggle(this)"></span>17 PATIENT COUNSELING INFORMATION</div>
<div id="DAKLINZA_previewText_34076-0" class="previewText">
                  Advise the patient to read the FDA-approved patient labeling <span>...</span>
</div>
</div>
<div id="DAKLINZA_collapsableElement_34076-0" style="margin-left:68px; margin-top: 20px;" class="collapseElement">
<div class="descriptionText"><text>
                  <p>Advise the patient to read the FDA-approved patient labeling (Patient Information).</p>
               </text></div>
<span id="DAKLINZA_collapsableElement_" class="safetySubheading"></span><div id="42229-5" class="safetySubdescription"></div>
<span style="font-size : 15px; font-weight : bold;">Drug Interactions</span><div><text>
                              <p>Inform patients of the potential for drug interactions with DAKLINZA, and that some drugs should not be taken with DAKLINZA [<content stylecode="italics">see <a href="#ID_21aa015e-677d-4e54-b06e-cd268f43b128">Contraindications (4)</a>, <a href="#ID_93a5ce24-f0c5-41e5-82c9-3d6cb19ade6b">Drug Interactions (7)</a>, and <a href="#ID_fd973a06-63f8-4471-a2de-584c0a88e03d">Clinical Pharmacology (12.3)</a>
                                 </content>].</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;">Symptomatic Bradycardia When Used in Combination with Sofosbuvir and Amiodarone</span><div><text>
                              <p>Advise patients to seek medical evaluation immediately for symptoms of bradycardia, such as near-fainting or fainting, dizziness or lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest pain, confusion or memory problems [<content stylecode="italics">see <a href="#ID_373737c1-1c3d-432d-8bc5-64cbc8867b32">Warnings and Precautions (5.2)</a>, <a href="#ID_4225c82a-ae5b-4b78-82ce-dcbff5089df5">Adverse Reactions (6.2)</a>, and <a href="#ID_ffe9ad53-99fb-46ee-abce-ac3fdf7343f3">Drug Interactions (7.3)</a>
                                 </content>].</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;">DAKLINZA Combination Therapy with Sofosbuvir</span><div><text>
                              <p>Inform patients that DAKLINZA should not be used alone to treat genotype 3 chronic hepatitis C infection. DAKLINZA should be used in combination with sofosbuvir for the treatment of genotype 3 HCV infection [<content stylecode="italics">see </content>
                                 <content stylecode="italics">
                                    <a href="#ID_f60e0659-e3d8-44a5-9372-047869643ec2">Indications and Usage (1)</a>
                                 </content>].</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;">Missed Doses</span><div><text>
                              <p>Instruct patients that if they miss a dose of DAKLINZA, the dose should be taken as soon as possible if remembered within the same day. However, if the missed dose is not remembered within the same day, the dose should be skipped and the next dose taken at the appropriate time. For instructions for missed doses of other agents in the regimen, refer to the respective prescribing information.</p>
                           </text></div>
<span style="font-size : 15px; font-weight : bold;">Hepatitis C Virus Transmission</span><div><text>
                              <p>Inform patients that the effect of treatment of hepatitis C infection on transmission is not known, and that appropriate precautions to prevent transmission of the hepatitis C virus during treatment should be taken.<br>
                                 <br>
                                 <br>
                              </p>
                           </text></div>
</div>
</div>
<div class="section"><div id="DAKLINZA_collapsableElement_42229-5" style="margin-left:68px; margin-top: 20px;" class="collapseElement"><div class="descriptionText"><text>
                  <p>
                     <br>Manufactured for:<br>Bristol-Myers Squibb Company<br>Princeton, NJ 08543 USA<br>Product of Ireland<br>
                     <br>1344554A0<br>
                     <br>DAKLINZA is a trademark of Bristol-Myers Squibb Company. Other brands uled are the trademarks of their respective owners.<br>
                     <br>
                  </p>
               </text></div></div></div>
<div class="section"></div>
<div class="section"></div>
<div class="section"></div>
</div>